Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syncytial virus in patients with influenza-like illness.

Kaku, Norihito; Kodama, Hina; Akamatsu, Norihiko; Ota, Kenji; Kosai, Kosuke; Morinaga, Yoshitomo; Narita, Yusuke; Matsumoto, Yasushi; Matsushita, Tetsuro; Mizuta, Yohei; Izumikawa, Koichi; Mukae, Hiroshi; Yanagihara, Katsunori

Kaku, Norihito; Kodama, Hina; Akamatsu, Norihiko; Ota, Kenji; Kosai, Kosuke; Morinaga, Yoshitomo; Narita, Yusuke; Matsumoto, Yasushi; Matsushita, Tetsuro; Mizuta, Yohei; Izumikawa, Koichi; Mukae, Hiroshi; Yanagihara, Katsunori.

Kaku N; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan; Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan. Electronic address: kaku-ngs@umin.ac.jp.
Kodama H; Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan.
Akamatsu N; Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan.
Ota K; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan; Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan.
Kosai K; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan; Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan.
Morinaga Y; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan; Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan; Department of Microbiology, Graduate School
Narita Y; Narita Naika Clinic, 2026-6 Yoshimuta-go, Nagayo cho, Nishisonogi-gun, Nagasaki, Japan.
Matsumoto Y; Matsumoto Naika, 257-1 Kohjiroki, Kunimi-cho, Unzen City, Nagasaki, Japan.
Matsushita T; Shinzato Medicare Group Shinzato Clinic, 3-20 Mori-machi, Nagasaki City, Nagasaki, Japan.
Mizuta Y; Menoto Hosiptal, 849-18 Koda-go, Nagayo cho, Nishisonogi-gun, Nagasaki, Japan.
Izumikawa K; Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan.
Mukae H; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan.
Yanagihara K; Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan; Department of Laboratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan.

J Infect Chemother ; 27(6): 820-825, 2021 Jun.

Article in English | MEDLINE | ID: covidwho-1045151

ABSTRACT

ABSTRACT

INTRODUCTION:

Digital immunoassays (DIAs) and molecular point-of-care (POC) tests for influenza were recently developed. We aimed to evaluate and compare the positive rate with molecular POC tests and DIAs in detecting influenza virus A, B and respiratory syncytial virus (RSV).

METHODS:

A prospective observational study was conducted in 2019-2020. Nasopharyngeal swab samples were collected from adult outpatients with influenza-like illness who visited four hospitals and clinics in Japan. DIAs were performed at each facility. The clinical diagnosis was determined based on the findings of DIAs, history taking, and physical assessment. Molecular POC test and reverse transcription polymerase chain reaction (RT-PCR) were performed later.

RESULTS:

A total of 182 patients were evaluated. The positive rate for influenza virus with molecular POC test was significantly higher than that with DIAs (51.6% versus 40.7%, p = 0.046). In patients who tested positive for influenza virus with only molecular POC test, the presence of influenza virus was confirmed by RT-PCR. In a comparison between the patients who were positive for influenza virus with only molecular POC test and those with both molecular POC test and DIA, the percentage of patients who sought consultation within 18 h after the onset of symptoms was significantly higher in the molecular POC test only group than in the both methods group (70.0% versus 43.2%, p = 0.044).

CONCLUSIONS:

A molecular POC test could contribute to the accurate diagnosis of influenza in patients with influenza-like illness, especially those who visited a hospital immediately after the onset of symptoms.

Subject(s)

Influenza A virus; Influenza, Human; Orthomyxoviridae; Respiratory Syncytial Virus Infections; Adult; Humans; Immunoassay; Influenza A virus/genetics; Influenza B virus/genetics; Influenza, Human/diagnosis; Japan; Orthomyxoviridae/genetics; Point-of-Care Systems; Point-of-Care Testing; Respiratory Syncytial Virus Infections/diagnosis; Sensitivity and Specificity

Keywords

Influenza; Molecular diagnostic techniques; Multicenter study; Point-of-care; Respiratory syncytial virus

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Orthomyxoviridae / Influenza A virus / Respiratory Syncytial Virus Infections / Influenza, Human Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google